Homology Medicines, Inc. (0T6G.L)
USD 1.87
(-4.64%)
USD 1.87
(-4.64%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 9.87 Million USD | -92.62% |
| 2022 | 133.88 Million USD | 11.23% |
| 2021 | 120.37 Million USD | -2.97% |
| 2020 | 124.06 Million USD | 17.83% |
| 2019 | 105.29 Million USD | 64.62% |
| 2018 | 63.95 Million USD | 120.75% |
| 2017 | 28.97 Million USD | 196.85% |
| 2016 | 9.76 Million USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 14.72 Million USD | 56.36% |
| 2024 Q2 | 4.5 Million USD | -69.38% |
| 2023 Q3 | 24.22 Million USD | -20.85% |
| 2023 Q4 | 9.41 Million USD | -61.14% |
| 2023 Q1 | 27.72 Million USD | -20.01% |
| 2023 FY | 92.68 Million USD | -30.78% |
| 2023 Q2 | 30.6 Million USD | 10.39% |
| 2022 Q1 | 37.87 Million USD | 18.24% |
| 2022 Q4 | 34.66 Million USD | 4.95% |
| 2022 Q2 | 28.32 Million USD | -25.22% |
| 2022 Q3 | 33.02 Million USD | 16.62% |
| 2022 FY | 133.88 Million USD | 11.23% |
| 2021 Q2 | 30.34 Million USD | 8.17% |
| 2021 FY | 120.37 Million USD | -2.97% |
| 2021 Q1 | 28.05 Million USD | 269.8% |
| 2021 Q4 | 32.03 Million USD | 6.99% |
| 2021 Q3 | 29.93 Million USD | -1.35% |
| 2020 Q4 | 7.58 Million USD | -9.93% |
| 2020 FY | 124.06 Million USD | 17.83% |
| 2020 Q2 | 8.79 Million USD | 13.17% |
| 2020 Q1 | 7.77 Million USD | 34.43% |
| 2020 Q3 | 8.42 Million USD | -4.21% |
| 2019 Q3 | 6.03 Million USD | 9.03% |
| 2019 Q1 | 4.85 Million USD | -4.52% |
| 2019 FY | 105.29 Million USD | 64.62% |
| 2019 Q4 | 5.78 Million USD | -4.27% |
| 2019 Q2 | 5.53 Million USD | 14.02% |
| 2018 Q2 | 4.52 Million USD | 18.26% |
| 2018 Q4 | 5.08 Million USD | 32.37% |
| 2018 FY | 63.95 Million USD | 120.75% |
| 2018 Q1 | 3.82 Million USD | 42.51% |
| 2018 Q3 | 3.84 Million USD | -15.11% |
| 2017 Q1 | 2.76 Million USD | 0.0% |
| 2017 FY | 28.97 Million USD | 196.85% |
| 2017 Q3 | 1.71 Million USD | -13.32% |
| 2017 Q4 | 2.68 Million USD | 56.33% |
| 2017 Q2 | 1.98 Million USD | -28.4% |
| 2016 FY | 9.76 Million USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Thermo Fisher Scientific Inc. | 10.25 Billion USD | 99.904% |
| Dynavax Technologies Corporation | 219.14 Million USD | 95.494% |
| Illumina, Inc. | 3.81 Billion USD | 99.741% |
| IQVIA Holdings Inc. | 2.05 Billion USD | 99.519% |
| Biogen Inc. | 5.2 Billion USD | 99.81% |
| Iovance Biotherapeutics, Inc. | 450.99 Million USD | 97.81% |
| Mettler-Toledo International Inc. | 1.08 Billion USD | 99.094% |
| Sarepta Therapeutics, Inc. | 1.36 Billion USD | 99.274% |
| Supernus Pharmaceuticals, Inc. | 529.01 Million USD | 98.133% |
| Waters Corporation | 943.51 Million USD | 98.953% |
| Perrigo Company plc | 1.52 Billion USD | 99.354% |
| uniQure N.V. | 285.08 Million USD | 96.536% |
| Agios Pharmaceuticals, Inc. | 408.8 Million USD | 97.584% |
| Amicus Therapeutics, Inc. | 427.65 Million USD | 97.691% |
| Atara Biotherapeutics, Inc. | 275.69 Million USD | 96.418% |
| bluebird bio, Inc. | 240.23 Million USD | 95.889% |
| Cara Therapeutics, Inc. | 142.46 Million USD | 93.068% |
| Imunon, Inc. | 21.03 Million USD | 53.044% |
| Myriad Genetics, Inc. | 600.1 Million USD | 98.354% |
| Neurocrine Biosciences, Inc. | 1.59 Billion USD | 99.381% |
| Nektar Therapeutics | 190.9 Million USD | 94.827% |
| Editas Medicine, Inc. | 247.3 Million USD | 96.007% |
| Verastem, Inc. | 92.08 Million USD | 89.276% |
| Walgreens Boots Alliance, Inc. | 40.6 Billion USD | 99.976% |
| Corbus Pharmaceuticals Holdings, Inc. | 13.9 Million USD | 29.006% |
| Heron Therapeutics, Inc. | 120.65 Million USD | 91.816% |
| Unity Biotechnology, Inc. | 44.66 Million USD | 77.892% |
| BioMarin Pharmaceutical Inc. | 1.74 Billion USD | 99.435% |
| Sangamo Therapeutics, Inc. | 228.68 Million USD | 95.682% |
| Evolus, Inc. | 189.75 Million USD | 94.796% |
| Adicet Bio, Inc. | 152.03 Million USD | 93.505% |
| Aclaris Therapeutics, Inc. | 12.14 Million USD | 18.664% |
| Regeneron Pharmaceuticals, Inc. | 2.81 Billion USD | 99.649% |
| Esperion Therapeutics, Inc. | 271.89 Million USD | 96.368% |
| FibroGen, Inc. | 398.11 Million USD | 97.52% |
| Agilent Technologies, Inc. | 2.11 Billion USD | 99.533% |
| OPKO Health, Inc. | 574.68 Million USD | 98.282% |
| Geron Corporation | 70.44 Million USD | 85.981% |
| Alnylam Pharmaceuticals, Inc. | 1.8 Billion USD | 99.451% |
| Exelixis, Inc. | 1.58 Billion USD | 99.378% |
| Viking Therapeutics, Inc. | 100.82 Million USD | 90.206% |
| Anavex Life Sciences Corp. | 55.75 Million USD | 82.289% |
| Intellia Therapeutics, Inc. | 551.56 Million USD | 98.21% |
| Zoetis Inc. | 2.76 Billion USD | 99.643% |
| Axsome Therapeutics, Inc. | 476.36 Million USD | 97.927% |
| Abeona Therapeutics Inc. | 48.5 Million USD | 79.64% |
| Vertex Pharmaceuticals Incorporated | 4.77 Billion USD | 99.793% |
| Kala Pharmaceuticals, Inc. | 39.15 Million USD | 74.778% |
| Ionis Pharmaceuticals, Inc. | 779.58 Million USD | 98.733% |
| Corcept Therapeutics Incorporated | 368.61 Million USD | 97.321% |
| Halozyme Therapeutics, Inc. | 299.31 Million USD | 96.701% |
| Blueprint Medicines Corporation | 722.86 Million USD | 98.634% |
| Insmed Incorporated | 949.26 Million USD | 98.96% |
| TG Therapeutics, Inc. | 198.47 Million USD | 95.025% |
| Incyte Corporation | 1.19 Billion USD | 99.171% |
| Emergent BioSolutions Inc. | 1.04 Billion USD | 99.054% |